肠道炎症患者对SARS-CoV-2免疫接种的全身与T细胞相关应答(STAR SIGN研究):生物制剂对第三剂mRNA疫苗接种效力的影响
这项前瞻性多中心病例对照研究纳入139例接受生物制剂治疗的炎症性肠病(IBD)患者和110名健康对照,评估第三剂mRNA疫苗接种后的体液和细胞免疫应答。抗TNF治疗的IBD患者抗刺突IgG浓度(几何均值2357.4 BAU/ml)低于非抗TNF治疗患者(5935.7 BAU/ml)和健康对照(5481.7 BAU/ml),且更多抗TNF治疗患者T细胞应答不足(20.5% vs 2.0%)。作者认为第四剂接种可能对这些患者有益。
要点
- 抗TNF治疗的IBD患者第三剂mRNA疫苗后抗刺突IgG几何均值2357.4 BAU/ml,低于非抗TNF治疗者5935.7 BAU/ml和健康对照5481.7 BAU/ml。
- 抗TNF治疗患者中15/73(20.5%)T细胞应答不足,健康对照仅2/100(2.0%),两组差异有统计学意义。
- 既往感染和接种mRNA-1273可提高抗体浓度,抗TNF治疗和接种至检测时间延长则降低抗体浓度。
核心结论
- 抗TNF治疗的IBD患者第三剂SARS-CoV-2 mRNA疫苗后体液和细胞免疫原性受损,第四剂接种可能对这些患者有益。
研究设计与样本
- 前瞻性、多中心、病例对照研究,纳入139例接受生物制剂治疗的IBD患者和110名健康对照,接种第三剂mRNA疫苗后2-16周检测血清抗SARS-CoV-2刺突IgG浓度。
主要发现
- 抗TNF治疗的IBD患者抗刺突IgG几何均值2357.4 BAU/ml(几何标准差3.3),低于非抗TNF治疗患者5935.7 BAU/ml(3.9;p<0.0001)和健康对照5481.7 BAU/ml(2.4;p<0.0001)。
- 多变量模型中,既往感染(几何均值比2.00 [95%CI 1.34-2.90])和接种mRNA-1273(1.53 [1.01-2.27])提高抗体浓度,抗TNF治疗(0.39 [0.28-0.54])和接种至检测时间延长(0.72 [0.58-0.90])降低抗刺突抗体。
- IBD患者抗体下降程度与是否抗TNF治疗无关,抗体浓度不能预测突破性感染。
- 细胞免疫与体液免疫应答不耦合,抗TNF治疗患者中15/73(20.5%)T细胞应答不足,健康对照2/100(2.0%),p=0.00031。
临床怎么用
- 作者认为第四剂接种可能对抗TNF治疗的IBD患者有益。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Immunosuppressed patients with inflammatory bowel disease (IBD) experience increased risk of vaccine-preventable diseases such as COVID-19. AIMS: To assess humoral and cellular immune responses following SARS-CoV-2 booster vaccination in immunosuppressed IBD patients and healthy controls. METHODS: In this prospective, multicentre, case-control study, 139 IBD patients treated with biologics and 110 healthy controls were recruited. Serum anti-SARS-CoV-2 spike IgG concentrations were measured 2-16 weeks after receiving a third mRNA vaccine dose. The primary outcome was to determine if humoral immune responses towards booster vaccines differ in IBD patients under anti-TNF versus non-anti-TNF therapy and healthy controls. Secondary outcomes were antibody decline, impact of previous infection and SARS-CoV-2-targeted T cell responses. RESULTS: Anti-TNF-treated IBD patients showed reduced anti-spike IgG concentrations (geometric mean 2357.4 BAU/ml [geometric SD 3.3]) when compared to non-anti-TNF-treated patients (5935.7 BAU/ml [3.9]; p < 0.0001) and healthy controls (5481.7 BAU/ml [2.4]; p < 0.0001), respectively. In multivariable modelling, prior infection (geometric mean ratio 2.00 [95% CI 1.34-2.90]) and vaccination with mRNA-1273 (1.53 [1.01-2.27]) increased antibody concentrations, while anti-TNF treatment (0.39 [0.28-0.54]) and prolonged time between vaccination and antibody measurement (0.72 [0.58-0.90]) decreased anti-SARS-CoV-2 spike antibodies. Antibody decline was comparable in IBD patients independent of anti-TNF treatment and antibody concentrations could not predict breakthrough infections. Cellular and humoral immune responses were uncoupled, and more anti-TNF-treated patients than healthy controls developed inadequate T cell responses (15/73 [20.5%] vs 2/100 [2.0%]; p = 0.00031). CONCLUSIONS: Anti-TNF-treated IBD patients have impaired humoral and cellular immunogenicity following SARS-CoV-2 booster vaccination. Fourth dose administration may be beneficial for these patients.
引用
- Woelfel S, Dütschler J, König M, et al. Systemic and T cell-associated responses to SARS-CoV-2 immunisation in gut inflammation (STAR SIGN study): effects of biologics on vaccination efficacy of the third dose of mRNA vaccines against SARS-CoV-2. Aliment Pharmacol Ther. 2022. PMID: 36307899. doi:10.1111/apt.17264
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。